DiscoverPharmaceutical ExecutiveKey Findings of the NIAGARA and HIMALAYA Trials
Key Findings of the NIAGARA and HIMALAYA Trials

Key Findings of the NIAGARA and HIMALAYA Trials

Update: 2024-11-08
Share

Description

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.






Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Key Findings of the NIAGARA and HIMALAYA Trials

Key Findings of the NIAGARA and HIMALAYA Trials

Pharmaceutical Executive Podcast